TY - JOUR
T1 - Pulmonary exacerbations in patients with primary ciliary dyskinesia
T2 - An expert consensus definition for use in clinical trials
AU - Lucas, Jane S.
AU - Gahleitner, Florian
AU - Amorim, Adelina
AU - Boon, Mieke
AU - Brown, Philippa
AU - Constant, Carolina
AU - Cook, Simon
AU - Crowley, Suzanne
AU - Destouches, Damien M.S.
AU - Eber, Ernst
AU - Mussaffi, Huda
AU - Haarman, Eric
AU - Harris, Amanda
AU - Koerner-Rettberg, Cordula
AU - Kuehni, Claudia E.
AU - Latzin, Philipp
AU - Loebinger, Michael R.
AU - Lorent, Natalie
AU - Maitre, Bernard
AU - Moreno-Galdó, Antonio
AU - Nielsen, Kim G.
AU - Özçelik, Uğur
AU - Philipsen, Lue Katrine Drasbæk
AU - Pohunek, Petr
AU - Polverino, Eva
AU - Rademacher, Jessica
AU - Robinson, Phil
AU - Snijders, Deborah
AU - Yiallouros, Panayiotis
AU - Carr, Siobhán B.
N1 - Publisher Copyright:
© ERS 2019.
Support statement: This study was supported European Union COST Action BM 1407. Funding information for this
article has been deposited with the Crossref Funder Registry
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Pulmonary exacerbations are a cause of significant morbidity in patients with primary ciliary dyskinesia (PCD) and are frequently used as an outcome measure in clinical research into chronic lung diseases. So far, there has been no consensus on the definition of pulmonary exacerbations in PCD. 30 multidisciplinary experts and patients developed a consensus definition for children and adults with PCD. Following a systematic review, the panel used a modified Delphi process with a combination of face-to-face meetings and e-surveys to develop a definition that can be used in research settings for children and adults with PCD. A pulmonary exacerbation was defined by the presence of three or more of the following seven items: 1) increased cough, 2) change in sputum volume and/or colour, 3) increased shortness of breath perceived by the patient or parent, 4) decision to start or change antibiotic treatment because of perceived pulmonary symptoms, 5) malaise, tiredness, fatigue or lethargy, 6) new or increased haemoptysis, and 7) temperature >38°C. The consensus panel proposed that the definition should be used for future clinical trials. The definition should be validated and the usability assessed during these studies.
AB - Pulmonary exacerbations are a cause of significant morbidity in patients with primary ciliary dyskinesia (PCD) and are frequently used as an outcome measure in clinical research into chronic lung diseases. So far, there has been no consensus on the definition of pulmonary exacerbations in PCD. 30 multidisciplinary experts and patients developed a consensus definition for children and adults with PCD. Following a systematic review, the panel used a modified Delphi process with a combination of face-to-face meetings and e-surveys to develop a definition that can be used in research settings for children and adults with PCD. A pulmonary exacerbation was defined by the presence of three or more of the following seven items: 1) increased cough, 2) change in sputum volume and/or colour, 3) increased shortness of breath perceived by the patient or parent, 4) decision to start or change antibiotic treatment because of perceived pulmonary symptoms, 5) malaise, tiredness, fatigue or lethargy, 6) new or increased haemoptysis, and 7) temperature >38°C. The consensus panel proposed that the definition should be used for future clinical trials. The definition should be validated and the usability assessed during these studies.
UR - http://www.scopus.com/inward/record.url?scp=85073261127&partnerID=8YFLogxK
U2 - 10.1183/23120541.00147-2018
DO - 10.1183/23120541.00147-2018
M3 - Article
AN - SCOPUS:85073261127
SN - 2312-0541
VL - 5
JO - ERJ Open Research
JF - ERJ Open Research
IS - 1
M1 - 00147-2018
ER -